Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

GLIOVACC

Financiado

Augmenting and broadening T cell responses to glioblastoma therapeutic vaccine...

Augmenting and broadening T cell responses to glioblastoma therapeutic vaccine platform based on HCMV expressing NKG2D ligands The development of an effective vaccine against human cancers is of tremendous importance. Glioblastoma multiforme (GBM) is the most malignant form of brain tumor with extremely poor survival. The human cytomegalovirus (HCMV) is i... ver más

31/07/2020

MEDRI

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

SVEUCILISTE U RIJECI MEDICINSKI FAKULTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-07-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

2 Participantes

MEDRI

149.97K€ | Lider

BABELDREAMS S.L.

350.00K€ | Participante

Proyectos interesantes

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

GPR-ICI Exploration of targeting GPR56 and its cancer cell ligand as... 150K€ Cerrado

Mel-Immune An integrative genetic approach for the exploration of melan... 3M€ Cerrado

CAN-IT-BARRIERS Disruption of systemic and microenvironmental barriers to i... 3M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 20 meses Fecha Inicio: 2018-11-15
Fecha Fin: 2020-07-31

Líder del proyecto

SVEUCILISTE U RIJECI MEDICINSKI FAKULTET

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto The development of an effective vaccine against human cancers is of tremendous importance. Glioblastoma multiforme (GBM) is the most malignant form of brain tumor with extremely poor survival. The human cytomegalovirus (HCMV) is involved in GBM pathogenesis suggesting that viral proteins might provide therapeutic targets. We propose a vaccination strategy against GBM based on a genetically modified HCMV that could target HCMV, as well as tumor specific antigens. The proposal builds on the successful implementation of the ERC-AdG StAdvInn, which investigates a murine cytomegalovirus (MCMV) expressing the NKG2D ligand RAE-1γ (RAE-1γMCMV), which has tremendous potential for strengthening the CD8 T cell response to a vectored antigen (Trsan et al, PNAS 2013). We have shown the strong potential of such vector to act as a CD8 T cell-based vaccine against malignant tumors (Trsan et al, Eur J Immunol 2017). Moreover, the efficiency of this vector can be enhanced by blocking immune checkpoints. We have constructed HCMV expressing the human NKG2D ligand ULBP2 (HCMV/ULBP2) and confirmed its efficacy in vitro and in humanized mice (Tomic et al, PLoS Pathog 2016). Here we propose to determine the capacity of the HCMV/ULBP2 vector in the immune control of GBM. In short, immune cells from GBM patients will be transferred to NSG mice that will be grafted with GBM from the same patients. Mice will be vaccinated with HCMV/ULBP2 vector expressing GBM associated neoantigens. Based on results with the RAE-1γMCMV in the melanoma model and with HCMV/ULBP2 in NSG humanized mice, we expect a strong effector CD8 T cell response to be generated in these mice resulting in the control of tumor in the NSG host. The proposed project activities include: development and validity testing of the prototype of the integrated vaccine vector, implementation of IPR protection and exploitation strategy. The results of this project will be used to establish the first in man trial in GBM bearing patients.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores